Altimmune stock surges 18% on positive trial results By Investing.com
Altimmune Inc. (NASDAQ:ALT) shares rose 18% after it reported positive topline results from its RECLAIM Phase 2 trial of pemvidutide for alcohol use disorder. The study met its primary endpoint with a statistically significant reduction in heavy drinking days versus placebo (4.20 vs 2.75 per week at week 24, p=0.0014). Secondary endpoints and safety data were also favorable, and the company plans an FDA End-of-Phase 2 meeting.
How this was made
The 30-second read
Why it matters
The trial met the primary endpoint with statistically significant reduction in heavy drinking days versus placebo and also met secondary endpoints described as registrational by the FDA, which can improve perceived regulatory readiness. The company also plans an End-of-Phase 2 meeting with the FDA to discuss the path forward.
Market read
A strong, specific Phase 2 efficacy readout with FDA-recognized registrational endpoints is a direct catalyst for ALT’s valuation and near-term trading momentum.
What to watch
The article does not include full safety/tolerability depth, durability beyond week 24, or guidance on Phase 3 design, which can materially change risk/reward after the initial spike.
Background
Altimmune is developing pemvidutide (a balanced glucagon/GLP-1 dual receptor agonist) for moderate to severe alcohol use disorder, with the RECLAIM Phase 2 trial now reporting topline results.
Ticker impact
Altimmune shares jumped 18% after announcing positive topline Phase 2 RECLAIM results for pemvidutide in alcohol use disorder.
Likely continued volatility and upside bias while traders price in an End-of-Phase 2 meeting and potential next-step trial/regulatory plan.
The article provides specific efficacy outcomes (primary endpoint p=0.0014, secondary endpoints including FDA-recognized registrational endpoints) plus a stated plan to request an End-of-Phase 2 meeting with the FDA.
Market effects
Reinforces investor appetite for addiction/GLP-1 related CNS metabolic pipelines, potentially lifting sentiment for adjacent clinical-stage biotechs.
Primarily US biotech tape impact via NASDAQ momentum.
Limited beyond biotech clinical-trial readthrough; no direct global macro linkage in the text.
Counterpoint
Topline Phase 2 success may not translate into Phase 3 efficacy or safety durability, so the move could fade if next-step details disappoint.
Key entities
- companyAltimmune Inc.
NASDAQ-listed developer of pemvidutide; reported positive topline Phase 2 RECLAIM results and plans an End-of-Phase 2 FDA meeting.
- drug_candidatePemvidutide
Investigational balanced glucagon/GLP-1 dual receptor agonist evaluated for alcohol use disorder.
- clinical_trialRECLAIM Phase 2 trial
Phase 2 study in alcohol use disorder; reported primary and secondary endpoint results in the article.
- regulatorFDA
Recognized certain secondary endpoints as registrational and will be engaged via an End-of-Phase 2 meeting.